Format

Send to

Choose Destination
See comment in PubMed Commons below
Rev Port Cardiol. 2013 Dec;32(12):1013-8. doi: 10.1016/j.repc.2013.05.004. Epub 2013 Nov 25.

[Position statement on bioresorbable vascular scaffolds in Portugal].

[Article in Portuguese]

Author information

1
Unidade de Intervenção Cardiovascular (UNICARV), Serviço de Cardiologia, Hospital de Santa Cruz-CHLO, Carnaxide, Portugal. Electronic address: rcteles@clix.pt.
2
Serviço de Cardiologia, Hospital Garcia de Orta, Almada, Portugal.
3
Serviço de Cardiologia, Hospital de Santo António-CHP, Porto, Portugal.
4
Serviço de Cardiologia, Hospital de Santa Marta-CHLC, Lisboa, Portugal; Serviço de Cardiologia, Hospital Espírito Santo, Évora, Portugal.
5
Serviço de Cardiologia, Hospital de São Bernardo-CHS, Setúbal, Portugal.
6
Unidade de Intervenção Cardiovascular (UIC), Hospital Particular do Algarve, Alvor, Portugal.
7
Serviço de Cardiologia, Hospital de São Teotónio, Viseu, Portugal.
8
Serviço de Cardiologia, Hospital Fernando Fonseca, Amadora, Portugal.
9
Serviço de Cardiologia, Hospital Universitário de Coimbra-CHUC, Coimbra, Portugal.
10
Centro do Coração, Hospital Cuf Infante Santo, Lisboa, Portugal.
11
Serviço de Cardiologia, Cento Hospitalar de Vila Nova de Gaia, Gaia, Portugal.
12
Serviço de Cardiologia, Hospital do Divino Espírito Santo, Ponta Delgada, Portugal.
13
Unidade de Intervenção Cardiovascular (UNICARV), Serviço de Cardiologia, Hospital de Santa Cruz-CHLO, Carnaxide, Portugal.

Abstract

BACKGROUND:

Bioresorbable vascular scaffolds (BVS) were recently approved for percutaneous coronary intervention in Europe. The aim of this position statement is to review the information and studies on available BVS, to stimulate discussion on their use and to propose guidelines for this treatment option in Portugal.

METHODS AND RESULTS:

A working group was set up to reach a consensus based on current evidence, discussion of clinical case models and individual experience. The evidence suggests that currently available BVS can produce physiological and clinical improvements in selected patients. There are encouraging data on their durability and long-term safety. Initial indications were grouped into three categories: (a) consensual and appropriate - young patients, diabetic patients, left anterior descending artery, long lesions, diffuse disease, and hybrid strategy; (b) less consensual but possible - small collateral branches, stabilized acute coronary syndromes; and (c) inappropriate - left main disease, tortuosity, severe calcification.

CONCLUSION:

BVS are a viable treatment option based on the encouraging evidence of their applicability and physiological and clinical results. They should be used in appropriate indications and will require technical adaptations. Outcome monitoring and evaluation is essential to avoid inappropriate use. It is recommended that medical societies produce clinical guidelines based on high-quality registries as soon as possible.

KEYWORDS:

Angioplastia coronária; Bioersorbable vascular scaffolds; Coronary angioplasty; Diabetes; Diabetic; Intervenção coronária percutânea; Percutaneous coronary intervention; Stent; Suportes vasculares restaurativos transitórios

PMID:
24287022
DOI:
10.1016/j.repc.2013.05.004
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ediciones Doyma, S.L.
    Loading ...
    Support Center